Abstract
This study uses wholesale medication acquisition costs and Medicare claims data to assess how prices of existing tumor necrosis factor inhibitors changed in response to the market entry of new tumor necrosis factor inhibitors.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adalimumab / economics
-
Antibodies, Monoclonal / economics
-
Arthritis, Rheumatoid / drug therapy
-
Certolizumab Pegol / economics
-
Costs and Cost Analysis*
-
Drug Approval
-
Drug Costs
-
Drug Industry*
-
Etanercept / economics
-
Health Expenditures
-
Humans
-
Infliximab / economics
-
Medicare Part D
-
Tumor Necrosis Factor Inhibitors / economics*
-
Tumor Necrosis Factor Inhibitors / therapeutic use
-
United States
Substances
-
Antibodies, Monoclonal
-
Tumor Necrosis Factor Inhibitors
-
golimumab
-
Infliximab
-
Adalimumab
-
Etanercept
-
Certolizumab Pegol